ABSTRACT
Large outdoor fires present a risk to the built environment. Wildfires that spread into communities, referred to as Wildland-Urban Interface (WUI) fires, have destroyed communities throughout the world, and are an emerging problem in fire safety science. Other examples are large urban fires including those that have occurred after earthquakes. Research into large outdoor fires, and how to potentially mitigate the loss of structures in such fires, lags other areas of fire safety science research. At the same time, common characteristics between fire spread in WUI fires and urban fires have not been fully exploited. In this paper, an overview of the large outdoor fire risk to the built environment from each region is presented. Critical research needs for this problem in the context offire safety science are provided. The present paper seeks to develop the foundation for an international research needs roadmap to reduce the risk of large outdoor fires to the built environment.
ABSTRACT
Parallel pipelines are frequently installed over long distances, due to the difficulty in creating or maintaining the required corridor. This implies that a release in one pipeline can seriously affect another one. The main risks associated with this domino effect are erosion by fluid-sand jets and the thermal action of jet fires. In this paper a survey has been performed on the accidents that have occurred, and the diverse associated domino sequences are analyzed. The probability of occurrence of domino effect is a function of the location of the hole, the jet direction and solid angle, the diameter of both pipelines and the distance between them. A mathematical model has been developed to estimate this probability. The model shows how the probability of domino effect decreases with the distance and diameter of the source pipe, and increases with the diameter of the target pipe. Its frequency can be estimated from this probability and from the frequency of the initiating pipe failure plus, in the case of jet fire impingement, the probability of ignition. The frequency of the target pipe failure thus calculated, always higher than its individual frequency, allows a more realistic risk analysis.
Subject(s)
Environmental Pollution/statistics & numerical data , Petroleum , Accidents, Occupational , Algorithms , Equipment Failure , Fires , Industry , Models, Theoretical , Petroleum Pollution , Probability , Risk Assessment , TransportationABSTRACT
Introducción: los ensayos clínicos constituyen un diseño de tipo experimental utilizado para evaluar cualquier actuación diagnóstica y terapéutica aplicada a humanos.Objetivo: evaluar los relatos de reacciones adversas a medicamentos, en cuanto a causalidad, gravedad, edad y grupos vulnerables en protocolos de ensayos clínicos con nuevos fármacos analizados en el Comité de Ética de la Investigación de la Secretaria de Salud de Brasilia. Distrito Federal, Brasil.Método: estudio observacional, descriptivo y transversal, en la modalidad de estudio de caso, se consideró como universo de trabajo los proyectos evaluados por el Comité de Ética en Investigación-CEI/SES/DF en el período comprendido entre los años 2000 y 2012. Resultados: el 59 por ciento de las investigaciones se correspondieron con estudios nacionales y el 41 por ciento con estudios internacionales. La industria farmacéutica fue la fuente financiadora en el 65 por ciento de los casos y en el 41 por ciento de ellos existió participación extranjera. De los medicamentos estudiados el 19 por ciento no poseían registro en la Agencia Nacional de Vigilancia Sanitaria-ANVISA y solo en el 9,5 por ciento de los ensayos se utilizó grupo control. Las reacciones adversas fueron consideradas como relacionadas a los medicamentos, posibles o improbables en el 15,7 por ciento, 19,8 por ciento y 63,6 por ciento, respectivamente.Conclusiones: la mayor parte de las investigaciones en las que se evaluaron nuevos medicamentos fueron conducidas por instituciones brasileñas y en la mayoría se recibió financiación internacional. La falta de registro de algunos de los nuevos productos en la agencia nacional reguladora y la no existencia de grupo control, en diferentes ensayos clínicos, fueron limitaciones identificadas en el proceso de evaluación. Se identificó la no existencia de modelos únicos legalmente validados para la evaluación de los eventos adversos a los medicamentos(AU)
Background: clinical trials are an experimental kind design used to assess any diagnostic and therapeutic performance applied to human beings.Aim: to assess the reports of adverse reactions to drugs, according to causality, seriousness, age and vulnerable groups in protocols of new drugs clinical trials analyzed in the Research Ethic Committee of Brasilia Health Secretariat, Federal District, Brazil. Method: cross-sectional, descriptive, observational study of case study kind. As universe of work, we took into account the projects assessed by the Research Ethic Committee of Brasilia Health Secretariat, Federal District (CEI/SES/DF in Portuguese) in the period from 2000 to 2012.Outcomes: 59 percent of the research corresponded to national studies and 41 percent to international ones. The pharmaceutical industry was the financeable source in 65 percent of the cases and there it was foreign participation in 41 percent of them. 19 percent of the studied drugs were not registered in the National Agency of Sanitary Surveillance (ANVISA in Portuguese) and control group was used in only 9,5 percent of the trials. The adverse reactions were considered as related to drugs, possible or improbable in 15,7 percent, 19,8 percent and 63,6 percent, respectively.Conclusions: most of the research where new drugs were assessed was carried out by Brazilian institutions and most of them received international financial support. The lack of registration of several new products in the national regulatory agency and not using control groups were limitations identified during the assessing process in several clinical trials. We identified the inexistence of unique models legally validated for the evaluation of adverse events to drugs(AU)
Subject(s)
Humans , Clinical Trials as Topic/adverse effects , Clinical Trials as Topic/ethics , Drug Evaluation/adverse effects , Reference Drugs , Drug Evaluation/ethics , Epidemiology, Descriptive , Cross-Sectional Studies , Observational Studies as Topic , BrazilABSTRACT
Introducción: los ensayos clínicos constituyen un diseño de tipo experimental utilizado para evaluar cualquier actuación diagnóstica y terapéutica aplicada a humanos. Objetivo: evaluar los relatos de reacciones adversas a medicamentos, en cuanto a causalidad, gravedad, edad y grupos vulnerables en protocolos de ensayos clínicos con nuevos fármacos analizados en el Comité de Ética de la Investigación de la Secretaria de Salud de Brasilia. Distrito Federal, Brasil. Método: estudio observacional, descriptivo y transversal, en la modalidad de estudio de caso, se consideró como universo de trabajo los proyectos evaluados por el Comité de Ética en Investigación-CEI/SES/DF en el período comprendido entre los años 2000 y 2012. Resultados: el 59 % de las investigaciones se correspondieron con estudios nacionales y el 41 % con estudios internacionales. La industria farmacéutica fue la fuente financiadora en el 65 % de los casos y en el 41 % de ellos existió participación extranjera. De los medicamentos estudiados el 19 % no poseían registro en la Agencia Nacional de Vigilancia Sanitaria-ANVISA y solo en el 9,5 % de los ensayos se utilizó grupo control. Las reacciones adversas fueron consideradas como relacionadas a los medicamentos, posibles o improbables en el 15,7 %, 19,8 % y 63,6 %, respectivamente. Conclusiones: la mayor parte de las investigaciones en las que se evaluaron nuevos medicamentos fueron conducidas por instituciones brasileñas y en la mayoría se recibió financiación internacional. La falta de registro de algunos de los nuevos productos en la agencia nacional reguladora y la no existencia de grupo control, en diferentes ensayos clínicos, fueron limitaciones identificadas en el proceso de evaluación. Se identificó la no existencia de modelos únicos legalmente validados para la evaluación de los eventos adversos a los medicamentos.
Background: clinical trials are an experimental kind design used to assess any diagnostic and therapeutic performance applied to human beings. Aim: to assess the reports of adverse reactions to drugs, according to causality, seriousness, age and vulnerable groups in protocols of new drugs clinical trials analyzed in the Research Ethic Committee of Brasilia Health Secretariat, Federal District, Brazil. Method: cross-sectional, descriptive, observational study of case study kind. As universe of work, we took into account the projects assessed by the Research Ethic Committee of Brasilia Health Secretariat, Federal District (CEI/SES/DF in Portuguese) in the period from 2000 to 2012. Outcomes: 59 % of the research corresponded to national studies and 41 % to international ones. The pharmaceutical industry was the financeable source in 65 % of the cases and there it was foreign participation in 41 % of them. 19 % of the studied drugs were not registered in the National Agency of Sanitary Surveillance (ANVISA in Portuguese) and control group was used in only 9.5 % of the trials. The adverse reactions were considered as related to drugs, possible or improbable in 15.7 %, 19.8 % and 63.6 %, respectively. Conclusions: most of the research where new drugs were assessed was carried out by Brazilian institutions and most of them received international financial support. The lack of registration of several new products in the national regulatory agency and not using control groups were limitations identified during the assessing process in several clinical trials. We identified the inexistence of unique models legally validated for the evaluation of adverse events to drugs.
